M. Locatelli-Sanchez

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 451 citations · Full text

Ifct-1501 Maps2, Immune Checkpoint Inhibitor, Pleural Disease +5

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

Pauline Corbaux, Denis Maillet, Amélie Boespflug et al. · European Journal of Cancer · 2019 · 80 citations · Full text

Similar Outcomes, Geriatric Oncology, Oncology +11

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

Denis Maillet, Pauline Corbaux, Jean‐Jacques Stelmes et al. · European Journal of Cancer · 2020 · 69 citations

Autoimmune Disease, Medicine, Immune Checkpoint Inhibitors +11

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier et al. · Journal of Clinical Oncology · 2017 · 51 citations

Lba8507 Background, Ifct-1501 Maps2, Multimodality +17

Lung Cancer May Increase Serum Procalcitonin Level

Virginie Avrillon, M. Locatelli-Sanchez, Laure Folliet et al. · Infectious Disorders - Drug Targets · 2015 · 47 citations